TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7924363

Group type: EXPERIMENTAL
Intervention: Carbicarb (1 mEq sodium/mL, n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sodium bicarbonate (1 mEq sodium/mL, n = 18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Carbicarb
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sodium bicarbonate
Number of subjects: 36
Study: 2685445

Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolytic therapy with avelysine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Systemic thrombolytic therapy with streptodekase
Number of subjects: 100
Study: 30745350

Group type: EXPERIMENTAL
Intervention: Loupes
Number of subjects: 40

Group type: COMPARATOR
Intervention: No loupes (Control)
Number of subjects: 40
Study: 29123351

Group type: EXPERIMENTAL
Intervention: Aromatherapy with essential oil of orange (4 drops on a pad, replaced every 1 hour for 6 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no aromatherapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aromatherapy with essential oil of orange
Number of subjects: 60
Study: 26247866

Group type: EXPERIMENTAL
Intervention: Stress condition (fMRI after stress exposure)
Number of subjects: 0
Study: 23831862

Group type: EXPERIMENTAL
Intervention: Essence of chicken
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21130990

Group type: EXPERIMENTAL
Intervention: Misoprostol 400 μg
Number of subjects: 1103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1103
Study: 20551490

Group type: EXPERIMENTAL
Intervention: Integration of physical activity into core curricula (30 minutes a day, 3 days a week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (no integration of physical activity)
Number of subjects: 0
Study: 17685172

Group type: EXPERIMENTAL
Intervention: Short-term graphomotor intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 15517308

Group type: EXPERIMENTAL
Intervention: 200 mg of alphaS1‐casein hydrolysate (TS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bovine skimmed milk powder (CS)
Number of subjects: 100
Study: 12390521

Group type: EXPERIMENTAL
Intervention: Sera containing anti-L-periaxin antibody injected into the endoneurium of rat sciatic nerve
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sera containing anti-L-periaxin antibody
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Depleted sera of anti-L-periaxin antibodies
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sera from age-matched control subjects
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sera from healthy control subjects
Number of subjects: 29
Study: 9916056

Group type: EXPERIMENTAL
Intervention: Vibrio cholerae 638 (El Tor, Ogawa) strain, doses ranging from 4 x 10(7) to 2 x 10(9) vibrios.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vibrio cholerae 638 (El Tor, Ogawa) strain
Number of subjects: 56
Study: 7574044

Group type: EXPERIMENTAL
Intervention: Low-dose acadesine (0.05 mg.kg‐1.min‐1)
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: High-dose acadesine (0.1 mg.kg‐1.min‐1)
Number of subjects: 633

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study: 2076720

Group type: EXPERIMENTAL
Intervention: Cimetropium bromide 5 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 6794709

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31769212

Group type: EXPERIMENTAL
Intervention: Ustekinumab (6 mg/kg intravenous infusion at week 0, then 90 mg subcutaneous injections every 8 weeks starting at week 8)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ustekinumab (after crossover from placebo)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ustekinumab (overall treatment)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 102
Study: 30583949

Group type: EXPERIMENTAL
Intervention: Centrifuged adipose tissue (CAT) treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no CAT treatment)
Number of subjects: 16
Study: 28000225

Group type: EXPERIMENTAL
Intervention: Isotretinoin rinses (minimum use of 12 months)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no isotretinoin rinses)
Number of subjects: 125
Study: 25566704

Group type: EXPERIMENTAL
Intervention: Continuous presternal bupivacaine infusion (5 mL/h bupivacaine 0.25%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study: 23987123

Group type: EXPERIMENTAL
Intervention: Low key group intervention focusing on obesity-related information, alleviation of social isolation, school and vocational integration, and improvement of self-esteem.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Conventional treatment focusing on weight loss.
Number of subjects: 600
Study: 21029506

Group type: EXPERIMENTAL
Intervention: DoiT intervention
Number of subjects: 747

Group type: COMPARATOR
Intervention: Control (water consumption)
Number of subjects: 747
Study: 20071288

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg tablets
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 30
Study: 17284136

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (mean dose 64.0 ± 23.3 mg, 0.75 mg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 15547531

Group type: EXPERIMENTAL
Intervention: Repeated spectroscopic pressure measurements at light (0.2 N), medium (0.4 N), and firm (0.6 N) levels
Number of subjects: 18
Study: 12003482

Group type: EXPERIMENTAL
Intervention: Braun Oral-B Battery toothbrush (D4)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Colgate Actibrush
Number of subjects: 114

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 114
Study: 9398007

Group type: EXPERIMENTAL
Intervention: 6 million units of interferon alfa 2b (IFN‐alpha2b) three times per week for 24 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 42
Study: 8177627

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 3221935

Group type: EXPERIMENTAL
Intervention: Levamisole immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study: 28671712

Group type: EXPERIMENTAL
Intervention: Rifaximin 550-mg BD (n=36)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo BD (n=18)
Number of subjects: 54
Study: 27475904

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study: 24917547

Group type: EXPERIMENTAL
Intervention: AZD3839 single-ascending-dose (SAD) study
Number of subjects: 0
Study: 22901586

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 62

Group type: COMPARATOR
Intervention: External beam radiotherapy
Number of subjects: 62
Study: 20551828

Group type: EXPERIMENTAL
Intervention: Written disclosure therapy (WDT) group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (writing about an emotionally neutral subject)
Number of subjects: 66
Study: 19073509

Group type: EXPERIMENTAL
Intervention: Tamoxifen (T) 20 mg per day orally
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Exemestane (E) 25 mg per day orally
Number of subjects: 578
Study: 15898901

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 26
Study: 11915990

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1402
Study: 9536229

Group type: EXPERIMENTAL
Intervention: Near erythemogenic therapy (70% of the 311 nm MED)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Far erythemogenic therapy (35% of the 311 nm MED)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Near erythemogenic therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Far erythemogenic therapy
Number of subjects: 13
Study: 7898843

Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin E2 (PGE2) gel
Number of subjects: 441

Group type: COMPARATOR
Intervention: Hygroscopic dilators
Number of subjects: 441
Study: 2795521

Group type: EXPERIMENTAL
Intervention: Classical acupuncture needling sites
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-classical (sham) needling sites
Number of subjects: 65
Study: 40345

Group type: EXPERIMENTAL
Intervention: mequitazine (two 10‐milligram doses a day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: dexchlorpheniramine (two 12‐milligram doses a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 30998965

Group type: EXPERIMENTAL
Intervention: Video knowledge translation strategy
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Written knowledge translation strategy
Number of subjects: 119

Group type: COMPARATOR
Intervention: No-information control
Number of subjects: 119
Study: 28714735

Group type: EXPERIMENTAL
Intervention: Pranayama plus education
Number of subjects: 43

Group type: COMPARATOR
Intervention: Education alone (Control)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Both groups (Pranayama and Control)
Number of subjects: 43
Study: 25456442

Group type: COMPARATOR
Intervention: Monocolumn spinal cord stimulation (SCS)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Multicolumn spinal cord stimulation (SCS)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Monocolumn SCS
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Multicolumn SCS
Number of subjects: 115
Study: 23822684

Group type: EXPERIMENTAL
Intervention: Endurance training (EG)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Resistance training (RG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 26
Study: 20712425

Group type: EXPERIMENTAL
Intervention: Misgav-Ladach (MLM)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Pfannenstiel-Kerr (PKM)
Number of subjects: 180
Study: 19561256

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no bevacizumab treatment)
Number of subjects: 82
Study: 16424245

Group type: EXPERIMENTAL
Intervention: Gadodiamide (0.1 mmol/kg)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (0.1 mmol/kg)
Number of subjects: 247
Study: 16249974

Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg b.i.d. + amoxicillin 1,000 mg + clarithromycin 500 mg (14 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg b.i.d. + amoxicillin 1,000 mg + clarithromycin 500 mg (14 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: pantoprazole + amoxicillin + clarithromycin
Number of subjects: 90

Group type: COMPARATOR
Intervention: lansoprazole + amoxicillin + clarithromycin
Number of subjects: 90
Study: 11346934

Group type: EXPERIMENTAL
Intervention: Radiation therapy in combination with lumpectomy and axillary dissection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Excision plus radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast-conserving therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axillary radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 0
Study: 9692697

Group type: EXPERIMENTAL
Intervention: Intravenous famotidine (bolus 20 mg, continuous infusion 4 mg/h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 10
Study: 8160985

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Awake control group
Number of subjects: 30
Study: 2820920

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29279181

Group type: EXPERIMENTAL
Intervention: Time lapse incubator (TLI)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Standard incubator (SI)
Number of subjects: 431
Study: 26834213

Group type: EXPERIMENTAL
Intervention: Baricitinib 4/8 mg
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Baricitinib (all doses)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Baricitinib 8 mg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Baricitinib < 4 mg
Number of subjects: 145
Study: 24315152

Group type: EXPERIMENTAL
Intervention: Linear ablation
Number of subjects: 119

Group type: COMPARATOR
Intervention: CFAE-guided ablation
Number of subjects: 119
Study: 23638770

Group type: EXPERIMENTAL
Intervention: Ultrabiotique(®) (Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantarum and Bifidobacterium breve) administered daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrabiotique(®)
Number of subjects: 0
Study: 20607528

Group type: EXPERIMENTAL
Intervention: Traditional Chinese herbs (Astragalus membranaceus, Salvia miltiorrhiza, and a decoction of six drugs)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Traditional Chinese herbs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no traditional Chinese herbs)
Number of subjects: 60
Study: 18329573

Group type: EXPERIMENTAL
Intervention: Manual instrumentation using K-type files
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rotary instrumentation using Hero 642
Number of subjects: 80
Study: 16584945

Group type: EXPERIMENTAL
Intervention: Motion palpation (MP) by team A (experienced chiropractor palpating, inexperienced performing treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motion palpation (MP) by team B (inexperienced chiropractor palpating, experienced performing treatment)
Number of subjects: 0
Study: 14551633

Group type: EXPERIMENTAL
Intervention: Intervention group (rehearsing alternative actions)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no rehearsal of alternatives)
Number of subjects: 99
Study: 10952955

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid daily for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8837559

Group type: EXPERIMENTAL
Intervention: c7E3 (glycoprotein IIb/IIIa antibody) - bolus and 12-hour infusion
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197

Group type: COMPARATOR
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Directional atherectomy
Number of subjects: 197
Study: 1430630

Group type: EXPERIMENTAL
Intervention: AIDS medical diagnosis
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: History of intravenous drug use (IVDU)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Non-AIDS medical diagnosis
Number of subjects: 360

Group type: COMPARATOR
Intervention: Non-IVDU history
Number of subjects: 360

Group type: COMPARATOR
Intervention: Sexual orientation (heterosexual vs. homosexual)
Number of subjects: 360
Study: 3781687

Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine therapy (two 500 mg tablets t.i.d. for 40 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 31727514

Group type: EXPERIMENTAL
Intervention: Systane Complete (artificial tears)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 46
Study: 28063099

Group type: EXPERIMENTAL
Intervention: 25-gauge PPV (group A)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 20-gauge PPV (group B)
Number of subjects: 15
Study: 26799373

Group type: EXPERIMENTAL
Intervention: Active stimulation (Treatment group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Active stimulation (Treatment group) during partial crossover
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group during partial crossover
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Safety assessment throughout the trial
Number of subjects: 94
Study: 25255578

Group type: EXPERIMENTAL
Intervention: Fructose (0.75 g/kg bodyweight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sucralose (sweetness-matched with fructose drink)
Number of subjects: 10
Study: 22190601

Group type: EXPERIMENTAL
Intervention: Circulating water blanket with forced-air warming blanket
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Forced-air warming blanket only
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Warming panels
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Forced-air devices
Number of subjects: 238
Study: 20394248

Group type: EXPERIMENTAL
Intervention: 0.5% epidural lidocaine plus fentanyl
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.08% epidural ropivacaine plus fentanyl
Number of subjects: 120
Study: 18812323

Group type: COMPARATOR
Intervention: Adjunctive device (catheter thrombus aspiration)
Number of subjects: 6415

Group type: COMPARATOR
Intervention: Adjunctive device (mechanical thrombectomy)
Number of subjects: 6415

Group type: COMPARATOR
Intervention: Adjunctive device (embolic protection)
Number of subjects: 6415

Group type: COMPARATOR
Intervention: Adjunctive device (all types)
Number of subjects: 6415
Study: 18089703

Group type: EXPERIMENTAL
Intervention: Pl/E2
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: FUL/E2
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: FUL/Pl
Number of subjects: 43
Study: 15262828

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose in first-use group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose in chronic therapy group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose in both groups
Number of subjects: 40
Study: 11350649

Group type: EXPERIMENTAL
Intervention: Betasom hydrogel (polyvinyl‐pyrrolidone‐iodine liposome hydrogel)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chlorhexidine‐gauze
Number of subjects: 36
Study: 9164777

Group type: EXPERIMENTAL
Intervention: Similac (milk)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fat
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Protein
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ross Special Formula
Number of subjects: 72

Group type: COMPARATOR
Intervention: Water
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lactose
Number of subjects: 72
Study: 7967421

Group type: EXPERIMENTAL
Intervention: Radiotherapy dose of 30 Gy in group 1 (stages I, IIA)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Radiotherapy dose of 25 Gy in group 2 (stages IIEA, IIB, IIIA)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Radiotherapy dose of 20 Gy in group 3 (stages IIEB, IIIB, IV)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Comparison with precursor studies HD-82 and HD-85
Number of subjects: 204
Study: 3668844

Group type: EXPERIMENTAL
Intervention: Ethanol (67 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethanol (0, 22, 45 g) and Diazepam (0, 10, 20 mg)
Number of subjects: 0
Study: 31883637

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 30761720

Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Insulin glargine U100 (IGlar U100)
Number of subjects: 210
Study: 27647021

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 147
Study: 26544853

Group type: EXPERIMENTAL
Intervention: MVA-B vaccine (3 intramuscular injections)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24565243

Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl (1 μg.kg(‐1) fentanyl, 1mg.kg(‐1) propofol)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol-alfentanil (10 μg.kg(‐1) alfentanil, 1mg.kg(‐1) propofol)
Number of subjects: 80
Study: 21601286

Group type: EXPERIMENTAL
Intervention: Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
Number of subjects: 4360
Study: 19570818

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhancing lesions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active T2 lesions
Number of subjects: 0
Study: 17127572

Group type: EXPERIMENTAL
Intervention: Therapeutic approach based on individual cognitive impairment patterns (single-blind randomised multiple-baseline experiment)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional dressing therapy (baseline phase)
Number of subjects: 8
Study: 15175794

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (rFVIIa) 90 microg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11360125

Group type: EXPERIMENTAL
Intervention: Iron (60 mg elemental iron/day) + albendazole (200 mg/day for 3 consecutive days, repeated 1 month later)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Albendazole (200 mg/day for 3 consecutive days, repeated 1 month later)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Iron + albendazole-placebo
Number of subjects: 177

Group type: COMPARATOR
Intervention: Albendazole + iron-placebo
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 177
Study: 8988080

Group type: EXPERIMENTAL
Intervention: Chiari malformation group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chiari malformation group with basilar invagination
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30